{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:59:42Z","timestamp":1790866782296,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001424","name":"ALF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018713","name":"Center for Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In advanced chronic kidney disease (CKD) evidence for lower systolic blood pressure (SBP) targets is limited and guideline recommendations are conflicting. We investigated the association between achieved SBP and major adverse cardiovascular events (MACE) in nephrology-referred patients with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this nationwide, observational cohort from the Swedish Renal Register\u2013chronic kidney disease (SRR-CKD), we included adults with CKD stages 3\u20135 referred to nephrology outpatient clinics between 2006 and 2017. Mean office SBP during the first year was categorized in incrementally higher SBP groups with 130\u2013&amp;lt;140 mmHg as reference. The primary outcome was MACE; secondary outcomes were its components and all-cause death, analyzed using cause-specific multivariable-adjusted flexible parametric survival models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 23\u2009317 patients (median age 72 years; 64% men; median estimated glomerular filteration rate (eGFR) 24 ml\/min\/1.73 m\u00b2), over a median follow-up of 2.5 years, 8556 (37%) experienced MACE and 7686 (33%) died. Compared with SBP 130\u2013&amp;lt;140 mmHg, SBP 120\u2013&amp;lt;130 mmHg was associated with lower risks of MACE [adjusted hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.87\u20130.99] and all-cause mortality (HR 0.93, 95% CI 0.87\u20130.99), whereas SBP \u2265160 mmHg was associated with higher risks of MACE (HR 1.38, 95% CI 1.28\u20131.49) and death (HR 1.29, 95% CI 1.20\u20131.38). MACE risk was nonproportional and declined over time in patients with SBP 100\u2013&amp;lt;120 mmHg, demonstrating lower MACE risk compared to 130\u2013&amp;lt;140 after 3 years. In continuous analyses, MACE risk was lowest around 125 mmHg and increased at higher SBP levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In nephrology-referred patients with advanced CKD, achieved SBP around 120\u2013&amp;lt;130 mmHg (near 125 mmHg) was associated with the lowest cardiovascular and mortality risk, while SBP \u2265140 mmHg, especially \u2265160 mmHg, was consistently associated with higher MACE risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag296","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:32:06Z","timestamp":1788219126000},"source":"Crossref","is-referenced-by-count":0,"title":["Achieved systolic blood pressure and cardiovascular outcomes in advanced chronic kidney disease"],"prefix":"10.1093","volume":"19","author":[{"given":"Ehab","family":"Al-Sodany","sequence":"first","affiliation":[{"name":"Karolinska Institutet Renal Unit, Department of Clinical Intervention and Technology (CLINTEC), , Stockholm \u00a0","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0994-8135","authenticated-orcid":false,"given":"Karolina","family":"Szummer","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medicine Huddinge, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"\u00d6sterman","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Renal Unit, Department of Clinical Intervention and Technology (CLINTEC), , Stockholm \u00a0","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Division of Clinical Epidemiology, Department of Medicine Solna, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medical Epidemiology and Biostatistics, , Stockholm ,","place":["Sweden"]},{"name":"Karolinska Institutet, Danderyd Hospital Division of Nephrology, Department of Clinical Sciences, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Heimb\u00fcrger","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Renal Unit, Department of Clinical Intervention and Technology (CLINTEC), , Stockholm \u00a0","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6501-8293","authenticated-orcid":false,"given":"Peter","family":"B\u00e1r\u00e1ny","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Renal Unit, Department of Clinical Intervention and Technology (CLINTEC), , Stockholm \u00a0","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8650-5795","authenticated-orcid":false,"given":"Marie","family":"Evans","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Renal Unit, Department of Clinical Intervention and Technology (CLINTEC), , Stockholm \u00a0","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026100110224979500_bib1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag040","article-title":"The updated global burden of chronic kidney disease: one death every 20 seconds","author":"Ortiz","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"2026100110224979500_bib2","doi-asserted-by":"publisher","first-page":"f5680","DOI":"10.1136\/bmj.f5680","article-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials","volume":"347","author":"Ninomiya","year":"2013","journal-title":"BMJ"},{"key":"2026100110224979500_bib3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis","volume":"2","author":"Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026100110224979500_bib4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2026100110224979500_bib5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"Clinical Practice Guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"KDIGO 2021","year":"2021","journal-title":"Kidney Int"},{"key":"2026100110224979500_bib6","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026100110224979500_bib7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/HYPERTENSIONAHA.121.18434","article-title":"Is the KDIGO Systolic Blood Pressure Target &lt;120 mm\u2009Hg for Chronic Kidney Disease Appropriate in Routine Clinical Practice?","volume-title":"Hypertension","author":"Dasgupta","year":"2022"},{"key":"2026100110224979500_bib8","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026100110224979500_bib9","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41440-025-02262-4","article-title":"Evaluating blood pressure targets in chronic kidney disease: a systematic review and meta-analysis","volume":"48","author":"Tada","year":"2025","journal-title":"Hypertens Res"},{"key":"2026100110224979500_bib10","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jamainternmed.2017.4377","article-title":"Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis","volume":"177","author":"Malhotra","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026100110224979500_bib11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"2026100110224979500_bib12","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2026100110224979500_bib13","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1681\/ASN.V10112426","article-title":"Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group","volume":"10","author":"Levey","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2026100110224979500_bib14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"2026100110224979500_bib15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-154-1-201101040-00003","article-title":"Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study","volume":"154","author":"Tonelli","year":"2011","journal-title":"Ann Intern Med"},{"key":"2026100110224979500_bib16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1053\/j.ajkd.2018.02.364","article-title":"Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: the CRIC (Chronic Renal Insufficiency Cohort) Study","volume":"72","author":"Koye","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2026100110224979500_bib17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0272-6386(03)00405-0","article-title":"Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP)","volume":"42","author":"Brown","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026100110224979500_bib18","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1097\/01.ASN.0000031805.09178.37","article-title":"Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP)","volume":"13","author":"Young","year":"2002","journal-title":"J Am Soc Nephro"},{"key":"2026100110224979500_bib19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1053\/j.ajkd.2012.06.017","article-title":"Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study","volume":"60","author":"Smink","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026100110224979500_bib20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S0272-6386(03)00742-X","article-title":"Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Tr\u00f8ndelag Health Study (HUNT), Norway","volume":"42","author":"Romundstad","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026100110224979500_bib21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000543201","article-title":"Associations of causes of chronic kidney disease with disease progression and mortality: insights from the Fukuoka Kidney Disease Registry Study","volume":"56","author":"Kitamura","year":"2025","journal-title":"Am J Nephrol"},{"key":"2026100110224979500_bib22","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40620-020-00930-x","article-title":"Systolic blood pressure and chronic kidney disease progression in patients with primary glomerular disease","volume":"34","author":"Kim","year":"2021","journal-title":"J Nephrol"},{"key":"2026100110224979500_bib23","doi-asserted-by":"publisher","first-page":"e009992","DOI":"10.1161\/JAHA.118.009992","article-title":"Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"7","author":"Ku","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026100110224979500_bib24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa1803180","article-title":"Effect of systolic and diastolic blood pressure on cardiovascular outcomes","volume":"381","author":"Flint","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100110224979500_bib25","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1097\/HJH.0000000000002927","article-title":"The association of SBP with mortality in patients with stage 1-4 chronic kidney disease","volume":"39","author":"Zhuo","year":"2021","journal-title":"J Hypertens"},{"key":"2026100110224979500_bib26","article-title":"Annual report 2025. Svenskt Njurregister (SNR). \u00c5rsrapport 2025. Stockholm: Svenskt Njurregister; 2025","author":"Registry","year":"2025"},{"key":"2026100110224979500_bib27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026100110224979500_bib28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/pds.3457","article-title":"The Nordic prescription databases as a resource for pharmacoepidemiological research\u2014a literature review","volume":"22","author":"Wettermark","year":"2013","journal-title":"Pharmacoepidemiol Drug"},{"key":"2026100110224979500_bib29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2307\/2670170","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Statist Assoc"},{"key":"2026100110224979500_bib30","first-page":"763","article-title":"A unified modelling framework for data analysis and methods development in Stata","volume":"20","author":"Merlin","year":"2020","journal-title":"StataJ"},{"key":"2026100110224979500_bib31","article-title":"StataCorp LLC","author":"Stata Statistical Software: Release 18","year":"2023"},{"key":"2026100110224979500_bib32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int"},{"key":"2026100110224979500_bib33","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.jacc.2009.05.073","article-title":"The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?","volume":"54","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026100110224979500_bib34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1097\/HJH.0000000000003168","article-title":"Blood pressure and kidney outcomes in patients with severely decreased glomerular filtration rate: a nationwide observational cohort study","volume":"40","author":"Al-Sodany","year":"2022","journal-title":"J Hypertens"},{"key":"2026100110224979500_bib35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026100110224979500_bib36","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"2026100110224979500_bib37","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.119.12697","article-title":"Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients","volume":"73","author":"Aggarwal","year":"2019","journal-title":"Hypertension"},{"key":"2026100110224979500_bib38","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jamainternmed.2020.5028","article-title":"Concordance between blood pressure in the systolic blood pressure intervention trial and in routine clinical practice","volume":"180","author":"Drawz","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026100110224979500_bib39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/ehjcvp\/pvw002","article-title":"Unobserved automated office blood pressure measurement in the Systolic Blood Pressure Intervention Trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg","volume":"2","author":"Kjeldsen","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026100110224979500_bib40","doi-asserted-by":"publisher","first-page":"e004536","DOI":"10.1161\/jaha.116.004536","article-title":"Implications of blood pressure measurement technique for implementation of Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"6","author":"Agarwal","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026100110224979500_bib41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/HYPERTENSIONAHA.116.08076","article-title":"Effect of intensive versus standard clinic-based Hypertension Management on Ambulatory Blood Pressure: results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study","volume":"69","author":"Drawz","year":"2017","journal-title":"Hypertension"},{"key":"2026100110224979500_bib42","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1161\/HYPERTENSIONAHA.117.10479","article-title":"Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial)","volume":"71","author":"Johnson","year":"2018","journal-title":"Hypertension"},{"key":"2026100110224979500_bib43","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1161\/HYPERTENSIONAHA.120.15300","article-title":"Effects of intensive versus standard office-based hypertension treatment strategy on white-coat effect and masked uncontrolled hypertension: from the SPRINT ABPM Ancillary Study","volume":"76","author":"Ghazi","year":"2020","journal-title":"Hypertension"},{"key":"2026100110224979500_bib44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/ki.2013.132","article-title":"Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease","volume":"84","author":"Mallamaci","year":"2013","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag296\/70885269\/sfag296.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag296\/70885269\/sfag296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag296\/70885269\/sfag296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:39:09Z","timestamp":1790865549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag296\/8777096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag296","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,31]]},"article-number":"sfag296"}}